MeiraGTx: Latest Eli Lilly Partnership Ignites Riboswitch Technology Potential

2025-11-12 15:30:30 ET

The last time I spoke about MeiraGTx Holdings plc ( MGTX ), it was in a Seeking Alpha article entitled "MeiraGTx: 2 Possible Near-Term BLA Filings Could Ignite Shareholder Value." With respect to this article, I noted the company advancing the use of its gene editing therapy AAV-AIPL1 for the treatment of patients with AIPL1-associated Leber congenital amaurosis 4 (LCA4). Specifically, there was to be a Marketing Authorization Application ((MAA)) of this gene therapy to the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) for the treatment of these patients with this eye disorder in Q4 of 2025. Not only was this to happen at that time, but also a Biologics License Application (BLA) to the FDA for this very same gene therapy under a similar pathway....

Read the full article on Seeking Alpha

For further details see: